News Sentiment

RNA sentiment intelligence

Atrium Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 12.15 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-2.5% over one week, -4.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Atrium Therapeutics’ new hire receives options and 3,500 stock units

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -2.5% Price reacting lower
Trend fit Trend inactive -4.0% over four weeks
Fair value -8.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 33
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 5
PR Newswire 5
TradingView 3
TradingKey 2
simplywall.st 2
Barron's 2
MT Newswires 1

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 17
Deals and strategy 4
Regulatory and legal 1
Balance sheet 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
AD HOC NEWS Direct company coverage

Avidity Biosciences Stock - Long-term strategy around RNA therapeutics

This article focuses on Avidity Biosciences' long-term strategy, clinical pipeline, and funding status as a pre-commercial biotechnology company. The company specializes in developing RNA-based therapies for rare muscle and neuromuscular diseases using antibody-oligonucleotide co

Tone
Positive 60/100
Event
Market update
Published
20 Jun 2026 14:47
Source
AD HOC NEWS
TradingKey Direct company coverage

Avidity Biosciences Inc (RNA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Avidity Biosciences Inc (RNA), highlighting its current earnings forecast score of 8.00 and an average price target of $72.00, with an upside of 96.08%. Based on analytics from 2 analysts, the stock receives a "Strong Buy" rating. Th

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 05:09
Source
TradingKey
TradingKey Direct company coverage

Avidity Biosciences Inc (RNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Avidity Biosciences Inc (RNA), detailing its business segments, regional revenue, and profit contribution. It shows that the company's revenue from the United States was $18.62 million, with segment and regional data not yet fully dis

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 23:40
Source
TradingKey
Moomoo Direct company coverage

Avidity Biosciences Price Target Announced at $25.00/Share by Leerink Partners

Leerink Partners has set a price target of $25.00 per share for Avidity Biosciences (NASDAQ: RNA). This new target suggests a potential for significant movement in the company's stock, according to the analyst firm. Investors will likely be watching how Avidity Biosciences reacts

Tone
Positive 68/100
Event
Analyst action
Published
15 May 2026 21:39
Source
Moomoo
Pharma Voice Direct company coverage

Novartis acquisition spin-off pioneers RNA therapeutics for the heart

Atrium Therapeutics, a spin-off from Avidity Biosciences following its acquisition by Novartis, is pioneering precision RNA therapeutics for rare, genetic cardiomyopathies. The company, launched with $270 million in funding and a Novartis-validated delivery platform, aims to deve

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 Mar 2026 14:11
Source
Pharma Voice